Maria F. Morelli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?

Journal: Frontiers in oncology

Published: December 25, 2025

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Application of Radiomics in Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: August 04, 2025

Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.

Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.

Journal: Cancers

Published: October 09, 2024

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.

Journal: BMC cancer

Published: August 05, 2024

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.

Journal: Cancers

Published: August 05, 2024

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.

Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.

Journal: Frontiers in oncology

Published: May 23, 2024

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.

Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.

Journal: Current oncology (Toronto, Ont.)

Published: December 16, 2023

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.

Journal: Cancer management and research

Published: July 12, 2023

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Journal: EClinicalMedicine

Published: March 07, 2023

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.

Journal: Cancers

Published: February 28, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026